Thought Leadership Content and Editorial Design
Pubrica writes and designs executive reports, white papers, bylined articles and supporting content for healthcare and life-science organisations, including leadership teams, communications teams, researchers, investor-relations, policy and advocacy teams and agencies. Our scientific writers and editorial designers interview your subject experts, build a fully sourced argument and design the finished piece. At the outset we identify which framework governs it: a promotional code such as the ABPI Code, the EFPIA Code or FDA rules where a medicine is named, advertising-disclosure rules where a placement is paid, or ICMJE and GPP 2022 where the content becomes a journal article. You receive the designed piece, a claim log with every figure sourced, and the chart data and build files.
A journal articleICMJE, GPP 2022, COPE
A white paper naming a medicineABPI, EFPIA, FDA, PAAB
A paid byline in a trade titleCAP Code, FTC
A ghost-written executive pieceYour own standard
An investor reportSecurities rules, not COPE
Argument → evidence → byline → disclosure → design
- Governing framework identified
- Sponsorship disclosed on the piece
- Every figure sourced
- Approved by the named author
- Editorial design that supports the argument
Service Scope
Eight Thought Leadership Service Areas, Available Individually
Most clients combine two or three of these services. The first, argument development, is the one most often omitted, and it is what distinguishes a piece from competitors’ content.
Who we serve
Organisations We Support with Thought Leadership Content
We support six types of client. Each has a position worth publishing and limited time to develop it into a well-sourced, readable piece.
Service Limitations
We do not promise reach, engagement, leads or growth, because these depend on many factors beyond a single piece of content. We are not a media agency: we do not buy placement, although we write the disclosure a paid placement requires. We do not write a bylined piece for anyone who has not read it and approved its claims. We do not write a promotional claim about a medicine or device that its evidence or label does not support, and if an argument depends on an assumption the data do not support, we tell you. We do not replace your medical, legal and regulatory review, which remains your responsibility. On ghostwriting, our rule is that the named person must be able to defend every sentence of the piece.
Compliance and Standards
Six Disclosure and Publication Frameworks for Thought Leadership
Much of this work is governed by none of these frameworks. Which framework applies depends on whether a piece names a product, whether a placement is paid and whether the content will become a journal article.
The ABPI Code, 2024 edition (United Kingdom)
The current edition, administered by the Prescription Medicines Code of Practice Authority, a division of the ABPI. It sets standards for the promotion of medicines to health professionals and other relevant decision makers in the UK — and its reach is wider than the word “promotion” suggests, catching material that mentions a medicine at all in contexts a communications team would not think of as advertising. The statutory backdrop is the Human Medicines Regulations 2012, under which advertising a prescription-only medicine to the general public is prohibited. If a white paper you are planning names a product and a UK clinician will read it, this is the document that governs it, not a publication-ethics code.
The EFPIA Code of Practice (European Union)
Covers the promotion of medicinal products to healthcare professionals and interactions with HCPs, healthcare organisations and patient organisations, with national association codes sitting underneath it and frequently going further. The statutory basis is Directive 2001/83/EC, under which advertising prescription-only medicines to the general public is prohibited across the Union. EFPIA’s own page did not state a version date for the consolidated Code when we read it on 22 September 2026, so we quote none and confirm the applicable version at the start of each project.
FDA promotional rules (United States)
Enforced by the Office of Prescription Drug Promotion under the Federal Food, Drug and Cosmetic Act — principally sections 201, 301 to 304 and 502 — with regulations at 21 CFR parts 200, 201 and 202. Three dates worth holding: the final rule requiring the major statement in direct-to-consumer television and radio advertisements to be presented in a clear, conspicuous and neutral manner was published 21 November 2023, effective 20 May 2024, with a compliance date of 20 November 2024, codified at 21 CFR 202.1(e)(1)(ii). The FDA’s final guidance on communications to healthcare providers about scientific information on unapproved uses was issued 6 January 2025. And its guidances on communications with payors and on communications consistent with FDA-required labeling date from 12 June 2018, updated 28 September 2021. OPDP publishes every untitled and warning letter it issues, by company and date, which makes the enforcement record on any claim type checkable rather than a matter of opinion.
ICMJE and GPP 2022 (only when it becomes a paper)
These are the journal bodies, and they belong on this page in exactly one circumstance: when the content is, or will become, a journal article. Then the four ICMJE authorship criteria apply and all four must be met by every author; writing assistance, technical editing, language editing and proofreading do not confer authorship and are acknowledged. Where the research is company-sponsored, GPP 2022 applies alongside — published in the Annals of Internal Medicine on 30 August 2022, stewarded by ISMPP, superseding GPP3 from 2015. Contributions are recorded in CRediT, ANSI/NISO Z39.104-2022, fourteen roles. These frameworks do not apply to executive reports that will not become journal articles.
Advertising disclosure (when money changed hands)
Sponsored content, native advertising, paid bylines and paid posts by clinicians or influencers all share one requirement across advertising regulators: a material connection between the advertiser and whoever carries the message must be disclosed clearly and up front. In the UK that is the CAP Code, enforced by the Advertising Standards Authority; in the United States it is the Federal Trade Commission’s endorsement rules. We write the disclosure into the piece rather than relying on a platform label, because a label a reader has to go looking for is not a disclosure. We could not open the current FTC text, so we confirm its detail at the time of writing rather than quoting a version here.
Where no code applies (most of this work)
A report on a health-system problem, an executive’s view of an industry shift, a data study your company ran — published on your own channels, naming no product, paid for by nobody. No formal code governs any of it, and there is no body that certifies corporate thought leadership. In these cases we apply our own house standard: a reader should be able to tell from the piece itself who wrote it, who paid for it, and what interest the author has in being believed.
Responsible Use of AI
Our Approach to AI Use in Thought Leadership Content
Thought leadership presents an argument that a named person is prepared to defend. We therefore use AI tools only in supporting tasks, and the argument and its wording remain the work of the author and our writers.
Why We Do Not Publish AI Accuracy Figures
Accuracy figures for AI tools are usually reported by the companies that sell them.
For this reason, Pubrica does not quote an accuracy figure of its own, because it would carry the same conflict. We tell you which tool was used on your project, at which stage, and what a human changed afterwards.
Our Process
Six Stages of a Thought Leadership Project
The process begins with interviews because the position worth publishing usually already exists within your organisation.
Subject Matter Expert Interviews
We hold a 90-minute interview with two or three people who work closest to the subject. The conversation covers what surprises them, what their customers misunderstand and where their views differ from competitors’, and the argument is developed from it. If no clear argument emerges, we tell you before you commission a report.
Regulatory and Disclosure Assessment
We establish whether the piece names a product, whether money changes hands, whose name is on it and whether it may become a journal article. These four answers determine which claims are available and where the disclosure sits, and settling them before drafting avoids rewriting.
One-Page Argument Agreement
We agree what the piece claims, what it rests on and what it commits to. The one-page agreement is signed off before drafting begins, so the report has a defined point of view rather than becoming a general survey.
Drafting with Fully Sourced Data
Every figure is recorded with its source, method and period. Journalists and competitors check unsourced statistics first. Where your own data support the argument, we state the sample, period and definitions so that readers can assess the finding.
Editorial Design
We develop the structure, hierarchy, typography and charts from the data. Charts use appropriate axes, show denominators and display uncertainty, so that no chart overstates a finding.
Author Review and Final Quality Checks
The named author reads the piece and approves every claim before it is published under their name. We then prepare the derivative articles, posts, slides and conference material, each written for its own format rather than cut down from the report.
Request a Free 90-Minute Content Consultation
A free consultation with the people closest to your subject, followed by a one-page note setting out the argument we see, the evidence it would rest on and the framework that governs publishing it. If the note concludes that there is no argument yet, you avoid commissioning a report that would not be read.
Please share details of your review process at the start of the project. In regulated organisations, medical, legal and regulatory review is thorough and can take time, and a piece written without knowing its requirements often has to be rewritten. Tell us who reviews, against which criteria and how long it takes, and we will write for that process.
Disclosure Framework Finder
Identify the Disclosure Framework That Applies to Your Content
Enter what the piece is, who is named on it, who reads it, whether money changed hands and whether it mentions a product. The finder identifies the framework that applies and what must be visible on the page. Where no code applies, it says so, which is the correct answer more often than many compliance sections suggest.
01
The governing framework for your piece, what must be disclosed, and where it goes on the page.
Runs in your browser · nothing sent anywhereOur underlying standard. A reader should be able to tell, from the piece itself, who wrote it, who paid for it and what interest the author has in being believed. Each framework above applies this principle to a particular kind of publication, and where no framework applies, the principle still does. Content that discloses its own sponsorship cannot later be exposed as undisclosed.
Sources and items we could not confirm. Authorship and acknowledgement: ICMJE Recommendations, PDF dated January 2026 — note that icmje.org’s HTML pages still showed the January 2024 text when we checked, so cite the PDF. GPP 2022: published in the Annals of Internal Medicine, 30 August 2022, stewarded by ISMPP; verified at ismpp.org. CRediT: ANSI/NISO Z39.104-2022. UK: the current edition of the ABPI Code is the 2024 edition, administered by the PMCPA — confirmed on the PMCPA’s own site on 22 September 2026. EFPIA: scope confirmed on efpia.eu on 22 September 2026; the site does not state a version date for the consolidated Code on the page we read, so we do not quote one. United States: OPDP’s statutory and regulatory basis and guidance dates from the FDA’s own OPDP regulatory information page; the clear, conspicuous and neutral final rule from the Federal Register, 21 November 2023. Items we could not confirm: the current version and effective date of the PhRMA Code and the AdvaMed Code, the current edition of the PAAB Code, the current Australian advertising Code instrument, and the current text of the FTC endorsement rules, because those sources would not open for us. Where they matter to a specific piece, we confirm them at the time of writing rather than carrying a version forward from a previous project.
Our experts
Your Thought Leadership Team
The same named team stays with your project from scoping to delivery. Your project coordinator introduces each member before work begins, and the handover records who completed each stage.
Reviews the scientific content for accuracy and confirms that each conclusion is supported by the evidence. Matched to your field rather than allocated from a rota.
Writes the content against the brief and the applicable code of practice, with every claim traceable to its reference.
Reviews the content for scientific accuracy, fair balance and compliance with the applicable code before it reaches your internal review.
Manages the timeline, keeps you informed at each stage and coordinates the team so that questions are answered and deadlines are met.
Sample work
Sample Work: Executive Report Argument Page
A report is read, quoted and approved in legal review when it makes a specific claim, every figure holds up and nothing material is undisclosed. This sample shows how we achieve that. Use the tabs to view each part, then open the full build pack.
Executive report build pack
Diagnostics company · 6,800 words · briefed as a product piece
Argument · sourcing · charts · disclosure
Product mentions: 0The report cleared review in one pass
- Claims in the draft
- 31 statements of fact, each logged with its source, the method behind it and the period it covers.
- Unsourced on arrival
- 9, all inherited from the client’s existing slide deck. Six were traceable to a real source; two traced to another company’s marketing material; one traced to nothing at all and had been repeated internally for three years.
- Removed
- 3: the two sourced to competitors’ marketing and the one with no traceable origin. Untraceable statistics are a common point of challenge from journalists.
- Narrowed
- 5. Each was true of a narrower population, period or geography than the sentence claimed. Restated at the width the source supports, which cost nothing and removed the piece’s only real vulnerability.
- The client’s own data
- One dataset, used for the central finding. Sample, period, definitions and collection method stated in the text — which is what makes a proprietary figure quotable rather than dismissible.
- References checked
- 24, each opened and read against the statement it supports. One had been superseded by a later analysis reaching a different conclusion, which is now cited alongside it.
11 charts in, 9 outEvery one rebuilt from the data
- Who published it
- The company, on page one, in the same type size as the title. Not a logo in a footer.
- Who wrote it
- Named: the company’s clinical affairs lead as author, with our editorial role acknowledged. Stating authorship openly prevents questions about who wrote the report.
- The interest
- Stated in the second paragraph: the company sells in this pathway and would benefit from the change the report argues for. Writing that plainly costs a sentence and removes the objection before a reader forms it.
- The external contributor
- A former commissioner quoted in the report was paid for their time. This was disclosed beside the quote rather than in an endnote, so readers see it without searching.
- Placement
- Published on the company’s own site and pitched to trade titles on editorial merit. Nothing paid, so no advertising disclosure arises. Had a placement been bought, it would have been labelled as advertising in the piece itself.
- Which codes applied
- None. No product named, no payment for placement, not a journal submission. So the applicable standard was ours, and it is one sentence: a reader should be able to tell who wrote it, who paid for it and what interest the author has in being believed.
Redacted extract · sector, pathway, client and every figure changedBuild pack, as delivered
One report, rebuilt from a product brief into a system argument. Use the tabs to see each part.
The argument decision simplified the rest of the project. Removing the product moved the piece outside the promotional codes, allowed it to clear medical, legal and regulatory review in a single pass and made the company’s position more credible with its intended audience.
The sourcing review found issues common to many reports. Nine unsourced claims were inherited from a slide deck, and one had no traceable origin despite three years of internal use. Figures that are reused often enough tend to lose their original source.
Ask for the sample work and you get a build pack for a piece like yours — same format, same sector, same review constraints.
Thought leadership · sample build pack
Executive Report Build Pack: Diagnostics Company, Health System Argument
A real build pack with the sector, the pathway, the client and every figure changed. The structure, the categories of finding and the documentation format are as delivered. Ask us and we will build one around a piece like yours.
1The argument page, agreed before drafting
One page, signed off by the client and the most useful document in the project. It is also the point at which the brief changed.
| Element | What was agreed |
|---|---|
| The brief as received | “A white paper on the value of earlier diagnosis.” The client’s product delivers earlier diagnosis, so written to that brief the piece is promotional material about a device — governed by the promotional code of every market it reaches, and read as marketing by the health-system audience it was aimed at. |
| What the interviews produced | Ninety minutes with two clinical affairs staff and a former commissioner. The argument that emerged: the bottleneck in this pathway is not diagnostic capability, it is the referral step between two budgets, and every attempt to solve it with technology has addressed the wrong constraint. |
| The claim | The central claim is stated in one sentence and commits to a specific position that readers can test. |
| What it rests on | Three public datasets, one proprietary dataset, and eleven interviews. Listed here so the evidence requirement is visible before the writing starts rather than assembled to fit a draft. |
| What it deliberately does not say | It does not name the product, does not claim a clinical outcome, and does not recommend a procurement decision. Written down, because the useful half of an argument page is the part that constrains it. |
| The decision on the product | The product was removed entirely. This takes the report outside the promotional codes, widens who inside a health system can share it, and makes the position more persuasive. It also meant the draft cleared medical, legal and regulatory review in one pass instead of three. |
We discuss this decision openly with clients. A client who needs a product piece should commission one and label it accordingly: it will be governed by the promotional rules, go through a longer review and be read as promotional material. It should not be presented as thought leadership.
2The claim log — 31 statements, 3 removed
| Finding | Count | Resolution |
|---|---|---|
| Claims logged with source, method and period | 31 | Every statement of fact in the report, in one table, with what it rests on. It is what makes the piece defensible and what makes the next report cheaper. |
| Unsourced on arrival | 9 | All inherited from the client’s existing slide deck. Six traced to a real source and were kept with the citation added. |
| Traced to a competitor’s marketing | 2 | Removed. A figure whose only origin is another company’s brochure is not evidence, and repeating it hands them the citation. |
| Traced to nothing | 1 | Removed. It had been used internally for three years and nobody could say where it came from. This is not carelessness; it is what happens to a number that gets reused often enough. |
| Narrowed | 5 | Each was true of a narrower population, period or geography than the sentence claimed. Restated at the width the source supports. |
| References opened and read | 24 | One had been superseded by a later analysis reaching a different conclusion. Both are now cited, with the disagreement described — which is more interesting than either alone. |
| The proprietary dataset | 1 | Carries the central finding. Sample, period, definitions and collection method stated in the text. An unexplained proprietary figure is dismissible; an explained one is quotable. |
3Charts, rebuilt from the data
| As drafted | As published | Why |
|---|---|---|
| Bar chart with the axis starting at 38% | Axis from zero | The truncation turned a four-point difference into an apparent doubling. The finding survives; it is four points. The overstated version is what a sceptical reader uses to dismiss the rest of the report. |
| Three charts showing percentages with no denominator | Denominators on every chart | One was 71% of fourteen respondents. That finding moved out of a chart and into a sentence saying what it is. |
| Point estimates throughout | Intervals where they exist; absence noted where they do not | The central finding came from a sample. Showing the uncertainty looks less confident and is considerably more persuasive to anyone who reads charts professionally. |
| A pie chart of respondent job titles | Removed | It served no part of the argument. Design effort spent on it is effort not spent on the chart carrying the finding. |
| A timeline of the company’s history | Removed | Relevant to the company but not to the reader, and it moved the report from argument towards brochure. |
| A colour scheme with six categorical colours | Two, plus grey | Six colours means a reader consults the legend for every chart. Two means they read the chart. |
4Disclosure, decided at draft stage
| Question | What was decided, and where it appears |
|---|---|
| Who published it | The company, named on page one in the same type size as the title. Not a logo in a footer. |
| Who wrote it | The company’s clinical affairs lead, named as author, having been interviewed and having approved every claim. Our editorial role is acknowledged. Stating authorship openly prevents questions about who wrote the report. |
| The interest | Second paragraph: the company sells in this pathway and would benefit from the change the report argues for. One sentence, and it removes the objection before the reader forms it. |
| The paid contributor | A former commissioner quoted in the report was paid for their time. Disclosed beside the quote rather than in an endnote. |
| Placement | Published on the company’s own site and pitched to trade titles on editorial merit. Nothing paid, so no advertising disclosure arises. Had a placement been bought, it would have been labelled as advertising in the piece itself — the requirement across advertising regulators is that a material connection is disclosed clearly and up front, and a platform’s own small label is not that. |
| Which codes applied | None. No product named, no paid placement, not a journal submission and no clinical claim, so our house standard applied. We state this openly rather than citing a publication-ethics body that has no jurisdiction over the work. |
| If it becomes a paper later | Flagged to the client at the start. Some journals decline material already published in substance, so the prior-publication policy of any likely target was checked before the report went out rather than discovered afterwards. |
5What was handed over
| Artefact | Why it matters afterwards |
|---|---|
| The report, designed, in print and screen versions | With the source files, so your own team can update it without coming back to us. |
| The argument page | One page. It is what the derivative articles, posts and conference material are all written from, and it keeps them saying the same thing. |
| The claim log | All 31 statements with their sources, methods and periods. It is what answers a journalist, a competitor or your own legal team in minutes. |
| The chart data and build files | Every figure with the data behind it, so a chart can be updated next year rather than redrawn. |
| The derivative set | Four articles, a slide version and social copy, each written for its own format rather than cut down from the report. |
| A note on what was not claimed | What the report deliberately does not say, and why. The shortest document in the pack and the one that stops a claim reappearing in the derivative work. |
What we do not report: downloads, shares, leads or attributed pipeline. We cannot isolate the contribution of one report to these outcomes, so we do not claim it. A report of this kind gives the organisation a defensible written position that its people can repeat consistently and that contains nothing undisclosed.
Benefits
Benefits and Limitations of Thought Leadership Content
We do not promise reach, leads or growth from a report. This work produces a defensible, documented position for your organisation.
Packages
Thought Leadership Service Packages
Each package specifies countable deliverables, named revision cycles and turnaround times, with a price shown for each tier. Everything below is priced at the same per-word logic as the rest of this site, with design and interview time on top where the format needs it.
Single Piece
A first white paper, a single bylined article, or a test of whether there is an argument worth building on
From $1,4001 white paper or article to 2,500 words · 1 revision
Delivery 10 business days
- ✓One 90-minute interview, which is where the argument comes from
- ✓The argument agreed on one page before drafting
- ✓Every claim logged with its source, method and period
- ✓Basic editorial layout, print and screen
- ✓Disclosure written into the piece, not added at sign-off
Credited in full against a programme commissioned within 90 days.
View a sample Select SingleReport and Supporting Content
Smaller organisations, or a first thought-leadership initiative that has to prove itself
From $3,2001 report or white paper · 2 articles · 1 revision cycle
Delivery 2–3 weeks
- ✓Everything in Single, at programme scale
- ✓Up to two interviews, and the argument built from them
- ✓Two derivative articles written for their own format, not cut down
- ✓Editorial design and layout, with charts rebuilt from your data
- ✓The claim log and chart data handed over
Where the piece names a product, the governing promotional code is confirmed before drafting.
View a sample Select StarterContent Programme
Organisations establishing authority in a domain, with a review process to work inside
From $8,9002–3 reports · 4–5 articles · 2 revision cycles
Delivery 4–6 weeks
- ✓Everything in Starter, across the programme
- ✓Content strategy: what each piece does that the others do not
- ✓Advanced editorial design with data visualisation and infographics
- ✓Brand and voice integration, working to your existing system
- ✓One argument page governing the whole programme
- ✓Written for your medical, legal and regulatory review from the start
Most clients choose this package because a set of related pieces makes the best use of the initial interviews and research.
View a sample Select ProfessionalAnnual Programme with a Named Team
Large organisations and global brands running a continuous programme rather than projects
From $22,0005+ reports · 8–10 articles · unlimited rounds within the agreed scope
Delivery 8–10 weeks, then to your calendar
- ✓Everything in Professional, at scale
- ✓A named strategist, writer and designer who stay with the account
- ✓Premium editorial design, data visualisation and interactive layouts
- ✓Ghost-written bylines across multiple named executives
- ✓Multi-market handling, where the strictest applicable rule governs
- ✓Quarterly review of content to keep claims current
Placement is not included and is not something we arrange. We write the disclosure; you or your agency buy the space.
View a sample Select EnterpriseDeliverables
The argument page
One pagesigned before drafting
Including what it deliberately does not say
States what the piece claims, what it rests on, what it commits to and what it excludes. Agreeing it early keeps a report, its articles and any conference talk consistent.
Deliverables
The claim log
Every figuresource, method, period
And the ones we removed, with why
A table that lets you answer questions from journalists, competitors or your legal team quickly. In the sample on this page it identified three claims with no traceable origin.
Deliverables
The chart data
Each chartwith its build file
Axes from zero, denominators shown
Every chart is supplied with its underlying data, so next year’s version can be updated rather than redrawn and anyone can see how each chart was built.
Available with any tier: additional interviews; editorial design of material written elsewhere; standalone chart rebuilds and data visualisation; translation and market adaptation as separate deliverables; conference and presentation versions; a sourcing audit of content you have already published; and expedited delivery where capacity allows.
Quality Assurance
Our Service Commitments and Limitations
Pubrica does not promise measurable growth from content. Our commitments and their limits are set out below.
The Pubrica guarantee
Revision Support Until Agreed Requirements Are Met
Within the agreed scope, we revise the piece until it makes the argument set out on the signed-off argument page, with no cap on rounds, and the writer remains available throughout your review process.
01
Every figure carries its source
Source, method and period, in a log you keep. Anything we cannot trace comes out, and we tell you where it came from — or that it came from nowhere.
02
Charts are built from the data
Axes from zero, denominators visible, uncertainty shown. We will not draw a chart to a brief, and we will say when one overstates its finding.
03
Named Author Approval
The named individual approves every claim before publication. This is a condition of our work and distinguishes writing with an author from writing in place of one.
04
Corrections at Our Cost
If an error such as a mis-sourced figure, a misdrawn chart or a missed disclosure originated with us, we correct it free of charge and inform you first.
Service limitations. We do not promise reach, engagement, downloads, leads, pipeline or growth, and we publish no figures claiming them. We are not a media agency and do not buy or arrange placement, although we write the disclosure a paid placement requires. We do not write a bylined piece for anyone who has not read it and will not stand behind its claims. We do not write promotional claims about a medicine or device that its evidence or approved labelling does not support, and where a piece names a product, we confirm the governing code in that market before drafting. We do not replace your medical, legal and regulatory review. We do not cite publication-ethics bodies as the compliance framework for corporate content; where no code applies, we say so and apply our own standard. If an argument depends on an assumption your data do not support, we tell you.
Free 90-Minute Content Consultation
One interview with the people closest to your subject, followed by a one-page note setting out the argument we see, the evidence it would rest on, the framework that governs publishing it and whether the piece is stronger with or without your product. There is no cost or obligation. If the note concludes that there is no argument yet, you avoid commissioning a report that would not be read.
Sourcing Audit of Published Content
Send us a piece you published in the last two years and we will trace every figure in it, with the first ten claims checked at no cost. In the sample on this page, three of thirty-one claims had no traceable origin and one had been repeated internally for three years. Such findings are common when figures are reused, and it is better to identify them before a journalist does.
Disclosure Written into the Draft
Funding, authorship, paid contributors and any interest you have in the argument are written into the first draft rather than negotiated at sign-off. A planned disclosure reads better and usually strengthens the argument. Where a placement is paid, the label appears in the piece itself, where readers can see it.
Brand Voice, Style and Review Integration
Your tone of voice, your terminology, your visual system and your approval workflow. Where you have a style guide we follow it; where you have several that disagree we will tell you, because that is usually why content from different teams does not read as one organisation. Where you work under medical, legal and regulatory review, we write for it from the start and attend the review rather than handing you a draft and a problem. Confidentiality under an NDA signed before any material moves, held under the UK GDPR within a quality management system certified to ISO 9001:2015.
Client Stories
Client Feedback on Thought Leadership Projects
The feedback below is paraphrased from clients and makes no claims about business outcomes.
“They told us the report was better without our product in it. It cleared medical, legal and regulatory review in one pass.”
“One of our headline statistics turned out to have no source at all. We had been using it for three years.”
“The interview found an argument none of us had noticed we were making. That became the whole programme.”
Thought leadership and editorial design FAQs
Thought Leadership and Editorial Design FAQs
If you are unsure whether your subject supports a report, a 90-minute consultation will establish this. Ask an expert — no quote required.
Executive reports and white papers; bylined articles and opinion pieces under a named individual; blogs and short-form posts; investor, board and stakeholder material; conference and presentation versions of all of it; and the editorial design, layout, data visualisation and infographics that make any of it worth opening. Across healthcare, the life sciences, medical technology, health policy and the organisations that sell into or regulate them. We also do the unglamorous half: the argument page the programme hangs from, the claim log that makes every figure defensible, and the sourcing audit of content you already published.
Only when the content is, or will become, a journal article. COPE and the ICMJE govern journal publication: authorship of research papers, editorial decisions, corrections, retractions and publication ethics. An executive report, investor white paper, blog or ghost-written byline is not journal publication, and no journal body has jurisdiction over it. Three questions decide what governs a piece. If it names a medicine or device, the promotional code of every market it reaches applies. If money changed hands for the placement, advertising-disclosure rules apply. If it will become a journal article, ICMJE and GPP 2022 apply. The framework finder on this page works through these questions.
Outside journals, writing with somebody is normal practice and no code prohibits it. Writing instead of somebody is a different thing, and the line is simple: could the named person defend every sentence in a room? Our working rule is that they are interviewed, they shape the argument, and they approve every claim before publication — and if a piece could go out under a name without that person having read it, it does not go out under that name. Inside journals the answer is different and much harder. Authorship is decided by the four ICMJE criteria, all of which every author must meet; a named individual who did not meet them cannot be an author, and a professional writer who is not acknowledged is the definition of the practice that publication ethics bodies were created to stop. Where the research is company-sponsored, GPP 2022 applies alongside. If a piece might travel from your website into a journal, decide that at the beginning, because retrofitting authorship is not possible.
No. Growth has many inputs, and a white paper is only one of them, so attributing pipeline to a single report confuses correlation with cause. This work produces narrower and more dependable results: a defensible written position, consistent messaging across your organisation, figures that hold up when checked and content with nothing undisclosed. If a supplier offers a figure for reach or leads, ask how it was measured and how that one piece’s contribution was isolated.
Most things. Material about a prescription medicine or a regulated device is capable of being promotion whatever format it takes — a white paper, a blog and a bylined article all count — and it is then governed by the promotional rules of every market it reaches. In the UK that is the ABPI Code, 2024 edition, administered by the PMCPA, over the Human Medicines Regulations 2012, under which advertising a prescription-only medicine to the general public is prohibited. In the EU it is the EFPIA Code over Directive 2001/83/EC, with the same prohibition. In the US it is FDA rules enforced by OPDP, plus the PhRMA and AdvaMed codes. In Canada, PAAB; in Australia, the Therapeutic Goods Advertising Code; in Japan, the PMD Act — which is what the Pharmaceutical Affairs Law was renamed in 2014, and is still widely cited under the old name. Our usual recommendation is to take the product out. We recommend removing the product rather than softening references to it. A piece that argues at the level of the disease, the evidence or the health-system problem reaches a wider audience under lighter rules, clears review faster and is usually more persuasive. The sample on this page shows this decision.
Layout places text into a template. Editorial design decides what the reader sees first, how the structure makes the argument clear, what line length and type size suit long reading and which findings need a chart. Much of the budget in this field goes on colour, illustration and covers, while most of the value lies in hierarchy, structure and charts built from the data. In the sample on this page, two charts were removed as unnecessary, one axis was rebuilt from zero because truncation made a four-point difference look like a doubling, and a six-colour palette was reduced to two colours plus grey so readers no longer needed the legend.
We interview the people whose voice the piece represents, which is why the process begins with a 90-minute conversation rather than a written brief. We also work from your style guide, your terminology and two pieces you were satisfied with. Where several style guides conflict, we point this out. Where the named person has a distinctive way of arguing, we keep it rather than reducing it to corporate house style.
Sometimes, and it is a decision to make at the start rather than discover afterwards. Journals differ in how they treat material already published in substance, and some will decline a paper whose central finding has appeared elsewhere. Check the prior-publication and preprint policy of any likely target journal before the white paper goes out. Two other things follow if a journal is in prospect: authorship has to be decided by the four ICMJE criteria rather than by who is senior, and any professional writing assistance is acknowledged rather than invisible. Where the research is company-sponsored, GPP 2022 applies. We will flag all of this at the argument-page stage, because the sequencing is free to get right and expensive to fix.
Yes. This page includes a complete sample: a build pack for an executive report that began as a product brief and was rebuilt as a health-system argument, with the sector, pathway, client and every figure changed. It shows the full process, including the three claims removed for having no traceable source, a chart axis corrected because it exaggerated a difference, and the recommendation to remove the client’s product from the report. If you would like a sample closer to your own work, we can prepare one around a similar piece. Client work is confidential, so any sample is redacted or composite. A sample shows method and sourcing discipline, but it cannot show whether the writer found your argument, which is what the free ninety minutes is for.
Related services
Related Services
Services that support the evidence behind a report, promotional content that names a product, and journal publication.
1THE EVIDENCE UNDERNEATHsearches and synthesis
Literature review and gap analysisThe evidence a report’s argument rests on, appraised rather than listed. Biostatistics and programmingWhere your own data are the story, analysed reproducibly.2WHEN A PRODUCT IS NAMEDpromotional rules
Scientific medical communicationOur hub page, covering the promotional frameworks for each market. Marketing communicationContent that is promotion, written and labelled as what it is.3IF IT BECOMES A PAPERjournals and authorship
Scientific and academic writingWhere ICMJE authorship and reporting guidelines take over. Editorial and quality supportIndependent editorial checking at a level agreed before the quote.Insights
Further Reading on Funder and Publication Rules
Three pieces on the funder and publication rules that shape where evidence can be published.
Request a Free 90-Minute Content Consultation
Book a free consultation with the people closest to your subject. Afterwards you receive a one-page note setting out the argument we see, the evidence it rests on, the framework that governs publishing it and whether the piece is stronger with or without your product. There is no cost or obligation.